+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Burns - Pipeline Review, H1 2019

  • ID: 4760857
  • Drug Pipelines
  • 93 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AlgiPharma AS
  • Alliance Pharma Plc
  • Anterogen Co Ltd
  • CFM Pharma Holding BV
  • Destiny Pharma Plc
  • Madam Therapeutics BV
  • MORE
Burns - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Burns - Pipeline Review, H1 2019, provides an overview of the Burns (Dermatology) pipeline landscape.

A burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.

Report Highlights

This latest pipeline guide Burns - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 3, 3, 2, 13, 4 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from 's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Burns (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AlgiPharma AS
  • Alliance Pharma Plc
  • Anterogen Co Ltd
  • CFM Pharma Holding BV
  • Destiny Pharma Plc
  • Madam Therapeutics BV
  • MORE
Introduction

Report Coverage

Burns - Overview

Burns - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Burns - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Burns - Companies Involved in Therapeutics Development

AlgiPharma AS

Alliance Pharma Plc

Amarantus Bioscience Holdings Inc

Anterogen Co Ltd

CFM Pharma Holding BV

Destiny Pharma Plc

Energenesis Biomedical Co Ltd

Madam Therapeutics BV

MallInckrodt Plc

MediWound Ltd

Phagelux Inc

Se-cure Pharmaceuticals Ltd

USV Pvt Ltd

viDA Therapeutics Inc

Burns - Drug Profiles

(cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(chlorpheniramine maleate + ibuprofen) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AGLE-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BH-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bromelains - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Dermatology and Immunology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENERGIF-711 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epidermal growth factor biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISN-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mul-1867 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neu-2000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NJ-01SS - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligomer G for Burn Wounds - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Activate FGFR for Cardiovascular, CNS, Dermatology and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pyrvinium pamoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize EPCR for Wounds and Burns - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAAP-148 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFR-9X0125 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

silver sulfadiazine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Burns - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium hypochlorite - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Burns and Dermatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tolasure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vanadis-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTI-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XF-70 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Burns - Dormant Projects

Burns - Discontinued Products

Burns - Product Development Milestones

Featured News & Press Releases

Jan 23, 2019: MediWound reports positive top-line data from NexoBrid study

Oct 15, 2018: Mallinckrodts Stratatech company awarded $26 million in additional BARDA funding for pediatric studies of stratagraft skin tissue in thermal burns

Sep 24, 2018: MediWound awarded additional BARDA contract valued Up to $43 Million for development of NexoBrid for sulfur mustard injuries

Sep 05, 2018: NexoBrid receives marketing authorization from Russia's Ministry of Health

Jul 18, 2018: U.S. FDA designates Mallinckrodt's StrataGraft as regenerative medicine advanced therapy

Jun 19, 2018: MediWound Expands Its NexoBrid Phase 3 Children Innovation Debridement Study (CIDS) to the U.S.

Jun 11, 2018: MediWound Completes Enrollment in NexoBrid U.S. Phase 3 DETECT Study

Jun 04, 2018: NexoBrid Receives Marketing Authorization From South Koreas Ministry of Health

Apr 09, 2018: MediWound’s NexoBrid to be Highlighted in Presentations at the American Burn Association 50th Annual Meeting Being Held on April 10-13, 2018 in Chicago

Jan 23, 2018: Amarantus Subsidiary Cutanogen Announces Issuance of US Patent 14/299,480 Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS

Jan 04, 2018: Amarantus Subsidiary Cutanogen Announces Patent Issuance in Hong Kong Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS

Oct 31, 2017: NeoMatrix Therapeutics Enters Clinical Stage as Investigational New Drug Application for NMT-cP12 Goes Into Effect

Sep 11, 2017: MediWound's NexoBrid Wins Best Poster Presentation Award at the 17th European Burns Association Congress

Sep 06, 2017: MediWounds NexoBrid Highlighted in 43 Presentations at the 17th European Burns Association Congress

Jul 19, 2017: BARDA Upsizes Contract with MediWound and Exercises Option to Fund Further NexoBrid Indications

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Burns, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Burns - Pipeline by AlgiPharma AS, H1 2019

Burns - Pipeline by Alliance Pharma Plc, H1 2019

Burns - Pipeline by Amarantus Bioscience Holdings Inc, H1 2019

Burns - Pipeline by Anterogen Co Ltd, H1 2019

Burns - Pipeline by CFM Pharma Holding BV, H1 2019

Burns - Pipeline by Destiny Pharma Plc, H1 2019

Burns - Pipeline by Energenesis Biomedical Co Ltd, H1 2019

Burns - Pipeline by Madam Therapeutics BV, H1 2019

Burns - Pipeline by MallInckrodt Plc, H1 2019

Burns - Pipeline by MediWound Ltd, H1 2019

Burns - Pipeline by Phagelux Inc, H1 2019

Burns - Pipeline by Se-cure Pharmaceuticals Ltd, H1 2019

Burns - Pipeline by USV Pvt Ltd, H1 2019

Burns - Pipeline by viDA Therapeutics Inc, H1 2019

Burns - Dormant Projects, H1 2019

Burns - Dormant Projects, H1 2019 (Contd..1), H1 2019

Burns - Dormant Projects, H1 2019 (Contd..2), H1 2019

Burns - Discontinued Products, H1 2019

List of Figures

Number of Products under Development for Burns, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AlgiPharma AS
  • Alliance Pharma Plc
  • Amarantus Bioscience Holdings Inc
  • Anterogen Co Ltd
  • CFM Pharma Holding BV
  • Destiny Pharma Plc
  • Energenesis Biomedical Co Ltd
  • Madam Therapeutics BV
  • MallInckrodt Plc
  • MediWound Ltd
  • Phagelux Inc
  • Se-cure Pharmaceuticals Ltd
  • USV Pvt Ltd
  • viDA Therapeutics Inc
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4760857
Adroll
adroll